Drug Trial Radar · NCT04416984
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
May 21, 2020
Primary completion
Feb 2029
Study completion May 2029
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Conditions
- Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501AGenetic
ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501ATime frame: 28 days
- Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501ATime frame: 33 days
- Phase 1b: Frequency and severity of ALLO-501A treatment-emergent adverse events (AEs), serious AEs, and AEs of special interestTime frame: Up to 60 months
- Phase 2: Overall Response Rate (ORR) assessed per Independent Review Committee (IRC)Time frame: Up to 60 months
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope
Duarte, California
UCLA Medical Center
Los Angeles, California
Stanford Cancer Institute
Palo Alto, California
Colorado Blood Cancer Institute
Denver, Colorado
Yale School of Medicine
New Haven, Connecticut
University of Miami
Miami, Florida
Advent Health
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Northside Hospital - Atlanta
Atlanta, Georgia
Augusta University
Augusta, Georgia
Loyola University Medical Center
Maywood, Illinois
Norton Cancer Institute
Louisville, Kentucky
Karmanos Cancer Institute
Detroit, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Providence Portland Medical Center
Portland, Oregon
Allegheny General Hospital
Pittsburgh, Pennsylvania
Avera Medical
Sioux Falls, South Dakota
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Texas Oncology
Dallas, Texas
MD Anderson Cancer Center - University of Texas
Houston, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Monash Medical Centre
Clayton, Victoria, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
QEII Health Sciences Centre-VG Site
Halifax, Nova Scotia, Canada
CHU de Québec -Université Laval; Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.